Drug Trial Radar · NCT04670679
A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
90
Actual
Start
Dec 15, 2020
Primary completion
Feb 1, 2026
Study completion Jun 1, 2026
Sponsor
- Lead sponsor
- Erasca, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 17, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
* To evaluate the safety and tolerability of escalating doses of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies in study participants with advanced or metastatic solid tumors. * To determine the Maximum Tolerated Dose (MTD) and/or recommended dose (RD) of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies. * To characterize the pharmacokinetic (PK) profile of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies. * To evaluate the antitumor activity of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies.
Conditions
- Advanced or Metastatic Solid Tumors
Interventions
ERAS-601Drug
Administered orally
CetuximabDrug
Administered via intravenous infusion
PembrolizumabDrug
Administered via intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Limiting Toxicities (DLT)Time frame: Study Day 1 up to Day 29
- Maximum tolerated dose (MTD)Time frame: Study Day 1 up to Day 29
- Recommended dose (RD)Time frame: Study Day 1 up to Day 29
- Adverse EventsTime frame: Assessed up to 24 months from time of first dose
- Plasma concentration (Cmax)Time frame: Study Day 1 up to Day 29
- Time to achieve Cmax (Tmax)Time frame: Study Day 1 up to Day 29
- Area under the curveTime frame: Study Day 1 up to Day 29
- Half-lifeTime frame: Study Day 1 up to Day 29
Locations
14 sites in 2 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Sarah Cannon Research Institute (Florida Cancer Specialists)
Sarasota, Florida
Massachusetts General Hospital
Boston, Massachusetts
Washington University
St Louis, Missouri
Comprehensive Cancer Centers of Nevada
Henderson, Nevada
Memorial Sloan Kettering Cancer Center
New York, New York
University of North Carolina
Chapel Hill, North Carolina
University of Cincinnati
Cincinnati, Ohio
University of Pennsylvania
Philadelphia, Pennsylvania
Sarah Cannon Research Institute (Tennessee Oncology)
Nashville, Tennessee
Mary Crowley Cancer Research
Dallas, Texas
The University of Texas MD Anderson Cancer Center
Houston, Texas
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
Linear Clinical Research
Perth, Western Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.